Salvat, the international laboratory that has developed and owns Cristalmina, Gama Relive, Tebarat and Cetraxal products, has submitted the NDA documentation for a new drug application to the U.S. Food and Drug Administration (FDA) for approval of Clobetasol, the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in patients undergoing eye surgery. The submission to the FDA follows the success of two phase III clinical trials conducted between 2020 and 2021. Cl...